Basics 4D Molecular Therapeutics, Inc. IPO Date: December 11, 2020 Sector: Healthcare Industry: Biotech Market Cap: $158.43M Activated in VL: True Average Daily Range Avg Daily Range: $0.66 | 3.53% Avg Daily Range (30 D): $0.15 | 4.40% Avg Daily Range (90 D): $0.17 | 4.34% Institutional Daily Volume Avg Daily Volume: .38M Avg Daily Volume (30 D): .37M Avg Daily Volume (90 D): .61M Trade Size Avg Trade Size (Sh.): 72 Avg Trade Size (Sh.) (30 D): 95 Avg Trade Size (Sh.) (90 D): 94 Institutional Trades Total Inst.Trades: 1,041 Avg Inst. Trade: $1.86M Avg Inst. Trade (30 D): $1.14M Avg Inst. Trade (90 D): $1.43M Avg Inst. Trade Volume: .11M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.87M Avg Closing Trade (30 D): $1.58M Avg Closing Trade (90 D): $1.02M Avg Closing Volume: 99.81K         News May 7, 2025 @ 8:44 AM Gene Therapy in Ophthalmology Industry Report 2025... Source: Researchandmarkets.Com Mar 4, 2025 @ 3:55 PM 2025 Market Prospects of Adeno-Associated Virus Ve... Source: Researchandmarkets.Com Feb 21, 2025 @ 6:00 PM Cell and Gene Therapies in Rare Disorders Market t... Source: Delveinsight Feb 19, 2025 @ 1:00 PM 4DMT to Participate in Upcoming Investor Conferenc... Source: 4D Molecular Therapeutics Feb 8, 2025 @ 7:30 PM 4DMT Presents Positive 52-Week Results from Phase ... Source: 4D Molecular Therapeutics Financials   TTM Q1 2025 Q4 2024 Basic EPS $-3.18 $-.86 $-.9 Diluted EPS $-3.18 $-.86 $-.9 Revenue $ .02M $ .01M $ M Gross Profit $ $ $ Net Income / Loss $ -176.44M $ -47.97M $ -49.67M Operating Income / Loss $ -203.33M $ -53.62M $ -56.12M Cost of Revenue $ $ $ Net Cash Flow $ -126.26M $ M $ -38.2M PE Ratio